Boston Scientific has finalized its acquisition of Baylis Medical, a Canadian healthcare technology company focused on designing solutions for interventional cardiologists and electrophysiologists, with an upfront payment of $1.75 billion.
The acquisition, designed to expand Boston Scientific’s structural heart disease and electrophysiology portfolios, was first announced in October 2021. It includes Baylis Medical’s VersaCross and NRG transseptal platforms, its SupraCross radiofrequency solutions and multiple guidewires, sheaths and dilators used to improve left heart access.
“The close of this acquisition allows Boston Scientific to integrate the Baylis platforms with our existing electrophysiology and structural heart offerings, further strengthening our position within the highest growth cardiology markets,” Joe Fitzgerald, executive vice president and president of cardiology for Boston Scientific, said in a statement. “We are now the only company to pair a comprehensive access portfolio with existing left-heart therapies such as left atrial appendage closure and atrial fibrillation ablation, providing physicians with a complete toolbox to treat patients with safety, efficacy and efficiency.”
Boston Scientific said it expects the acquisition to be “approximately one cent accretive to adjusted earnings per share in 2022 and increasingly accretive thereafter.” The company’s full presentation about the deal is available on its website.
Related Cardiology Economics Content:
HeartFlow calls off plans to merge, go public due to ‘unfavorable market conditions’
Medicare spending on cardiology, interventional cardiology declined $906M in 2020
Philips enters agreement to acquire Cardiologs
Boston Scientific acquires Baylis Medical’s cardiology business for $1.75B
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.